Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-21 20:26:15 UTC |
---|
Update Date | 2014-12-24 20:25:50 UTC |
---|
Accession Number | T3D2708 |
---|
Identification |
---|
Common Name | Ethchlorvynol |
---|
Class | Small Molecule |
---|
Description | Ethchlorvynol is only found in individuals that have used or taken this drug. It is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. |
---|
Compound Type | - Drug
- Hypnotic and Sedative
- Metabolite
- Organic Compound
- Organochloride
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 1-chloro-3-ethyl-1-penten-4-yn-3-ol | 1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol | 3-(beta-chlorovinyl)-1-pentyn-3-ol | 3-(β-chlorovinyl)-1-pentyn-3-ol | Aethyl-chlorvynol | Arvynol | Etchlorvinolo | Ethchlorovynol | Ethchlorvinol | Ethchlorvinyl | Ethclorvynol | Ethochlorvynol | Ethychlorvynol | ethyl β-chlorovinyl ethynyl carbinol | Nostel | Placidyl | Roeridorm | Serenesil | β-chlorovinyl ethyl ethynyl carbinol |
|
---|
Chemical Formula | C7H9ClO |
---|
Average Molecular Mass | 144.599 g/mol |
---|
Monoisotopic Mass | 144.034 g/mol |
---|
CAS Registry Number | 113-18-8 |
---|
IUPAC Name | 1-chloro-3-ethylpent-1-en-4-yn-3-ol |
---|
Traditional Name | etclorvinol |
---|
SMILES | [H]\C(Cl)=C(\[H])C(O)(CC)C#C |
---|
InChI Identifier | InChI=1/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+ |
---|
InChI Key | InChIKey=ZEHYJZXQEQOSON-AATRIKPKNA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H). |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic oxygen compounds |
---|
Class | Organooxygen compounds |
---|
Sub Class | Carbonyl compounds |
---|
Direct Parent | Ynones |
---|
Alternative Parents | |
---|
Substituents | - Ynone
- Tertiary alcohol
- Acetylide
- Chloroalkene
- Haloalkene
- Vinyl halide
- Vinyl chloride
- Hydrocarbon derivative
- Organochloride
- Organohalogen compound
- Alcohol
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
|
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Liquid |
---|
Appearance | Not Available |
---|
Experimental Properties | Property | Value |
---|
Melting Point | < 25°C | Boiling Point | 28.5-30°C | Solubility | 1.43e-01 g/L | LogP | 1.8 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-9100000000-2996a215de7a6e753815 | 2017-08-28 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (1 TMS) - 70eV, Positive | splash10-009i-9600000000-5560a4de50772eb686d4 | 2017-10-06 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0002-3900000000-198eb76a2aa919525f42 | 2017-07-25 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0002-3900000000-e1616a7a6e75f2940d8c | 2017-07-25 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0159-9000000000-b25f488adecb3fd0ff42 | 2017-07-25 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0006-4900000000-2980fab2cceb6fc96107 | 2017-07-26 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0006-3900000000-a6b1e1a57494f22868dd | 2017-07-26 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0a59-9400000000-b1fe9dd4623953d5d8ba | 2017-07-26 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-004i-6900000000-725ac670d608f579f9b1 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-016u-9200000000-376cadd129a6109c1500 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-002b-9100000000-33378000f2ae89d4dfd8 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0006-3900000000-ab92305130e98160aea2 | 2021-09-23 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-001i-9000000000-c2fa753da65a4bac80a1 | 2021-09-23 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-001i-9000000000-c2fa753da65a4bac80a1 | 2021-09-23 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Oral, rapidly absorbed from gastrointestinal tract. |
---|
Mechanism of Toxicity | Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. |
---|
Metabolism | About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.
Half Life: Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours. |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. |
---|
Symptoms | Symptoms of overdose include thrombocytopenia. |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00189 |
---|
HMDB ID | HMDB14335 |
---|
PubChem Compound ID | 5281077 |
---|
ChEMBL ID | CHEMBL591 |
---|
ChemSpider ID | 4444534 |
---|
KEGG ID | C07833 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 4882 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Ethchlorvynol |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Ethchlorvynol |
---|
References |
---|
Synthesis Reference | Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas.
Pfizer & Co., Inc. |
---|
MSDS | T3D2708.pdf |
---|
General References | - Drugs.com [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|